Financial Data and Key Metrics Changes - Adjusted net profits attributable to owners grew 64.7% year-over-year to RMB 907 million [3] - Overall revenue increased by 28.8% year-over-year to RMB 3.86 billion [17] - Gross profit in 2025 was RMB 2.84 billion, a year-on-year increase of 24.6%, with a gross margin of 73.6% [21][22] - The adjusted net profit attributable to owners was around RMB 970 million, reflecting a year-over-year increase of 64.7% [26] Business Line Data and Key Metrics Changes - Revenue from the core business of photo, video, and design products grew by 41.6% year-over-year to RMB 2.95 billion [18] - Paying subscribers for productivity tools grew 67.4% year-on-year, primarily driven by DesignKit and Kaipai [14] - Revenue from international markets grew by 37.4% year-over-year, accounting for 38% of total revenue in 2025 [18] Market Data and Key Metrics Changes - Monthly active users (MAU) grew 3.8% year-over-year to 276 million [13] - Paying subscribers grew 34.1% year-over-year to 16.91 million [13] - The penetration rate of Kaipai agents increased to approximately 11% [11] Company Strategy and Development Direction - The company focuses on two core strategies: productivity and globalization [13] - Plans to build AI agent teams to enhance e-commerce content creation and improve user engagement [5][7] - Aiming to optimize recommendation mechanisms and launch attractive features to enhance user stickiness [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of productivity tools and the positive impact of AI capabilities on business performance [32][34] - The company anticipates a gradual increase in ARPU growth as subscription rates improve [17] - Management acknowledged the challenges posed by competition but emphasized the company's unique positioning in vertical markets [48][49] Other Important Information - The company has officially discontinued the cosmetic supply chain management services, classifying it as a discontinued operation [17] - A share buyback plan of up to HKD 300 million was announced, reflecting confidence in future development [29] Q&A Session Questions and Answers Question: Paying subscribers are slightly lower than the first half of the year, and MAU is slightly lower than those in June - Management noted that the decrease in MAU is a snapshot of the past month and attributed it to the absence of blockbuster features in December [32][33] Question: Expectations for the year 2026 and the contribution of agents to subscriptions - Management indicated that the overall growth rate for 2026 is expected to be similar to 2025, with a focus on productivity tools globally [35][36] Question: Relationship between agent functions and ARPU enhancement - Management explained that the introduction of agents has led to increased token consumption, contributing to ARPU growth [62]

Financial Data and Key Metrics Changes - In 2025, the group operating income was CNY 435 billion, an increase of 7.7% year-on-year. Insurance revenue reached CNY 288 billion, up by 3.4%. Group OPAT attributable to shareholders was CNY 36 billion, up by 6.1%, while net profit was CNY 53.5 billion, up by 19% [4][5] - The group EV stood at CNY 613 billion, reflecting a 9.1% increase from the end of 2024. The number of customers increased by 3.5% to 190 million, and AUM approached CNY 3.9 trillion, up by 9.8% [4][5] Business Line Data and Key Metrics Changes - The life insurance business achieved written premiums of CNY 211.6 billion, up by 4.5%. The core agent headcount was 46,000, with a 13-month persistence ratio exceeding 90% [9][10] - The P&C business recorded primary premium income of CNY 201 billion, with auto insurance premiums at CNY 110 billion (up by 3%) and non-auto premiums at CNY 91 billion (down by 3%). The underwriting combined ratio improved to 97.5%, down by 1.1 percentage points year-on-year [12][13] Market Data and Key Metrics Changes - The bank channel achieved written premiums of CNY 61.6 billion, up by 46.4%, with regular pay FYP at CNY 17 billion, up by 43%. The share of mid-tier customers and above reached 41%, up by 1.8 percentage points [11] - The NEV business generated CNY 25 billion in premiums, accounting for 22% of total auto premiums, with a renewal rate of 78.1% for individual customers [13][71] Company Strategy and Development Direction - The company aims to enhance its core business competitiveness, focusing on value-driven growth and improving operational efficiency. It plans to accelerate innovation in technology and expand inclusive insurance offerings nationwide [24][26] - The strategic focus includes health and elderly care, internationalization, and AI integration to improve service capabilities and customer experience [24][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of China's economy and the importance of adapting to a new interest rate environment. They emphasized the need for steady progress while ensuring quality and efficiency in operations [3][22] - The company anticipates both opportunities and challenges in the insurance industry, with a focus on technological advancements and demographic shifts creating new needs for risk protection [21][22] Other Important Information - The MSCI ESG rating was upgraded to the highest AAA level, reflecting the company's commitment to sustainable development [8] - The company has implemented a new accounting standard, which has positively impacted net assets, showing a CAGR of 9.5% since its introduction [7][8] Q&A Session All Questions and Answers Question: What do you think was your achievement for the 14th Five-Year Plan? - Management noted progress in market position, transformation results, and growth in new business drivers, particularly in P&C and life insurance sectors [19][20] Question: How was the bank channel performing? - The bank channel is progressing as planned, with significant improvements in regular premium business and partnerships with major banks [28][30] Question: What is the outlook for 2026? - The company aims for higher quality and stronger resilience, focusing on core business performance and advancing three major strategies [40][42] Question: How will the company maintain solvency amid interest rate changes? - Management emphasized improved business quality and asset-liability matching as key factors in maintaining strong solvency ratios [32][34] Question: What are the plans for AI investment? - The company is committed to large-scale AI adoption across core business scenarios to enhance efficiency and customer experience [25][80]

Financial Data and Key Metrics Changes - In 2025, the group operating income was CNY 435 billion, an increase of 7.7% year-on-year. Insurance revenue reached CNY 288 billion, up by 3.4%. Group net profit was CNY 53.5 billion, up by 19% [5][6] - The group OPAT attributable to shareholders was CNY 36 billion, reflecting a growth of 6.1% [5][7] - The group EV stood at CNY 613 billion, up 9.1% from the end of 2024, with net assets increasing by 3.7% to CNY 302 billion [5][8] Business Line Data and Key Metrics Changes - The life insurance business achieved written premiums of CNY 211.6 billion, up 4.5%, with a core agent headcount of 46,000 and a 13-month persistence ratio exceeding 90% [9][10] - The bank channel saw a significant increase in written premiums, reaching CNY 61.6 billion, up by 46.4%, with regular pay FYP growing by 43% [11] - The P&C business recorded primary premium income of CNY 201 billion, with auto insurance premiums at CNY 110 billion (up 3%) and non-auto premiums at CNY 91 billion (down 3%) [12][13] Market Data and Key Metrics Changes - The number of customers increased by 3.5% to 190 million, and the group AUM approached CNY 3.9 trillion, up by 9.8% [6] - The underwriting combined ratio for P&C business improved to 97.5%, down by 1.1 percentage points year-on-year, with underwriting profit rising by 81% to CNY 4.8 billion [12][13] Company Strategy and Development Direction - The company aims to enhance operational efficiency and service capability, focusing on becoming a top-tier insurance company with market leadership and international competitiveness [17][26] - CPIC plans to accelerate innovation in technology, expand inclusive insurance offerings, and strengthen agricultural support systems [24][26] - The company is committed to a health and elderly care strategy, enhancing specialized operations in health insurance and building a closed-loop pension finance system [24][26] Management's Comments on Operating Environment and Future Outlook - Management noted that the insurance industry is entering a critical phase with both opportunities and challenges, emphasizing the need for steady progress while ensuring quality and efficiency [22][23] - The company will focus on integrating AI into core business scenarios to boost efficiency and reshape processes [25][40] - Management expressed confidence in maintaining strong solvency ratios and improving business quality despite market volatility [32][34] Other Important Information - The MSCI ESG rating was upgraded to the highest AAA level, reflecting the company's commitment to sustainable development [9] - The company has launched various initiatives in health and elderly care, including CPIC Home and internet-based services [21][56] Q&A Session All Questions and Answers Question: What do you think was your achievement for the 14th five-year period? - Management highlighted growth in market position, transformation results, and improvements in health and elderly care services [20][21] Question: How was the bank channel performing? - Management confirmed that the bank channel is progressing as planned, with significant improvements in business quality and customer mix [28][30] Question: What is the outlook for 2026? - Management aims for higher quality and stronger resilience, focusing on core business performance and new growth drivers [36][40] Question: How will the company maintain solvency amid interest rate changes? - Management emphasized improved business quality and asset liability matching as key factors in maintaining strong solvency ratios [32][34] Question: What are the plans for AI investment? - Management plans to drive large-scale AI adoption across core business scenarios to enhance efficiency and customer experience [25][80]

Financial Data and Key Metrics Changes - In 2025, the group operating income was CNY 435 billion, an increase of 7.7% year-on-year. Insurance revenue reached CNY 288 billion, up by 3.4%. Group net profit was CNY 53.5 billion, up by 19% [3][4] - The group OPAT attributable to shareholders was CNY 36 billion, reflecting a growth of 6.1%. The group EV stood at CNY 613 billion, up by 9.1% from the end of 2024 [3][5] - The number of customers increased by 3.5% to 190 million, and the group AUM approached CNY 3.9 trillion, up by 9.8% [4] Business Line Data and Key Metrics Changes - The life insurance business achieved written premiums of CNY 211.6 billion, up by 4.5%. The core agent headcount was 46,000, with a 13-month persistence ratio exceeding 90% [7][9] - The bank channel recorded written premiums of CNY 61.6 billion, up by 46.4%, with regular pay FYP increasing by 43% [10] - The P&C business reported primary premium income of CNY 201 billion, with auto insurance premiums at CNY 110 billion (up by 3%) and non-auto premiums at CNY 91 billion (down by 3%) [11][12] Market Data and Key Metrics Changes - The underwriting combined ratio for P&C business improved to 97.5%, down by 1.1 percentage points year-on-year, with underwriting profit amounting to CNY 4.8 billion, up by 81% [11] - The NEV business generated CNY 25 billion in premiums, accounting for 22% of total auto premiums, with a renewal rate of 78.1% for individual customers [12][55] Company Strategy and Development Direction - The company aims to enhance operational efficiency and service capability to become a top-tier insurance company with market leadership and international competitiveness [15] - Future strategies include focusing on health and elderly care, internationalization, and AI adoption to drive efficiency and optimize customer experience [21][33] - The company plans to strengthen agricultural support systems and expand inclusive insurance offerings nationwide [20] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of China's economy and the importance of adapting to a new interest rate era, emphasizing the need for steady progress while ensuring quality and efficiency [19][20] - The company anticipates both opportunities and challenges in the insurance industry, particularly with demographic shifts and technological advancements [19][20] Other Important Information - The MSCI ESG rating was upgraded to the highest AAA level, reflecting the company's commitment to sustainable development [6] - The company has implemented a new accounting standard, resulting in a CAGR of 9.5% in net assets since its adoption [6] Q&A Session Summary Question: Achievements in the 14th Five-Year Plan and outlook for the 15th Five-Year Plan - Management noted significant progress in market position, transformation results, and growth drivers, particularly in P&C and life business [17][18] Question: Bank channel performance and future initiatives - The bank channel has met expectations, with improvements in regular pay business and partnerships with SOE banks [23][24] Question: Solvency ratio and maintaining dividend payouts - The company reported improved solvency due to better business quality and asset-liability matching, ensuring stability in dividend payouts [26][27] Question: Outlook for 2026 and profitability expectations - Management expressed confidence in maintaining solid performance, focusing on quality growth and operational efficiency [29][31]

Financial Data and Key Metrics Changes - Hua Medicine achieved a revenue growth of 93% in 2025, with sales reaching close to CNY 500 million, driven by a 91% increase in the number of packs sold [3][19][20] - The gross profit margin improved due to economies of scale, with the price per tablet reduced by 8.2% [20][24] - The company reported a significant reduction in distribution costs and selling expenses, which dropped to 33% of sales from nearly 60% in 2024 [20][21] Business Line Data and Key Metrics Changes - The establishment of over 180 professional sales teams contributed to the sales growth, covering over 3,000 hospitals and reaching over 150,000 patients in mainland China [4][19] - The commercialization strategy shifted from relying on partners to an in-house team, enhancing market access and sales performance [4][19] Market Data and Key Metrics Changes - Hua Medicine expanded its market access through the registration of dorzagliatin in Hong Kong and plans to penetrate Southeast Asia, targeting over 100 million diabetes patients [5][16] - The company received a five-year extension on its composition of matter patent, ensuring market exclusivity until 2034 [5][24] Company Strategy and Development Direction - The company is focusing on expanding its glucose homeostasis technology platform and exploring new indications for dorzagliatin, including obesity and neurodegenerative diseases [18][28] - Hua Medicine aims to leverage its digital platform for commercialization and enhance the productivity of its sales team [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sales targets of CNY 1 billion by 2027, citing patent protection, stable pricing, and effective promotion strategies as key factors [34][39] - The company is optimistic about the long-term growth potential, especially as it continues to gather real-world evidence supporting the efficacy of dorzagliatin [22][42] Other Important Information - The company is exploring partnerships for international expansion and potential in-licensing opportunities to enhance its product portfolio [57] - Hua Medicine is committed to maintaining a strong capital position, with CNY 1 billion in gross cash available at the end of the year [24] Q&A Session Summary Question: What are the sales targets for the next two years? - Management remains confident in achieving CNY 1 billion in sales by 2027, supported by patent protection and stable pricing strategies [34][36] Question: What is the progress on the pipeline for the second generation GKA? - Management indicated that promising data from the second generation will guide interactions with regulatory agencies for product launch [33][34] Question: What are the operational expenses expected in the coming years? - Selling expenses are expected to stabilize around 30-35%, while R&D expenses will be maintained at approximately 30% to support ongoing research [46][52]

Financial Data and Key Metrics Changes - Hua Medicine achieved a revenue growth of 93% in 2025, with sales reaching approximately RMB 500 million, driven by a 91% increase in packs sold compared to 2024 [3][19][20] - The gross profit margin improved due to economies of scale, with a reduction in tablet price by 8.2% [20][24] - The company reported a significant decrease in losses, almost halving from previous periods, and achieved profitability for the first time [23][24] Business Line Data and Key Metrics Changes - The establishment of over 180 professional sales teams contributed to the sales growth, covering over 3,000 hospitals and reaching over 150,000 patients in mainland China [4][19] - The commercialization strategy shifted from relying on partners to an in-house team, which has proven effective in driving sales [4][19] Market Data and Key Metrics Changes - Hua Medicine expanded its market access through the introduction of dorzagliatin in Hong Kong and plans to penetrate Southeast Asia, targeting over 100 million diabetes patients [5][16] - The company received a five-year extension on its composition of matter patent, ensuring market exclusivity until 2034 [5][24] Company Strategy and Development Direction - The company is focusing on expanding its glucokinase activator program into new disease areas, including obesity and neurodegeneration, while maintaining a strong emphasis on diabetes management [2][18] - Hua Medicine is also exploring partnerships for international expansion and potential in-licensing opportunities to enhance its product offerings [28][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sales targets of RMB 1 billion by 2027, citing patent protection, stable pricing, and an effective sales strategy as key factors [32][34] - The company is optimistic about the future growth trajectory, supported by positive real-world evidence and increasing physician engagement [22][42] Other Important Information - Hua Medicine is advancing its clinical pipeline, with ongoing studies exploring the efficacy of dorzagliatin in combination with other therapies, including GLP-1 agonists [12][15] - The company is committed to maintaining a strong capital position, with RMB 1 billion in gross cash available at the end of the year [24][25] Q&A Session Summary Question: Regarding sales targets and peak sales expectations - Management remains confident in achieving RMB 1 billion in sales by 2027, supported by patent protection and pricing strategies [32][34] Question: Pipeline progress and regulatory interactions - Management indicated that promising data from the second-generation GKA will guide interactions with regulatory agencies for product launch [33][34] Question: Operating expenses and commercialization strategy - Management outlined plans to maintain selling expenses while investing in sales force expansion, with R&D expenses expected to remain around 30% of sales [45][51]

Financial Data and Key Metrics Changes - Hua Medicine achieved a revenue growth of 93% in 2025, with sales reaching close to CNY 500 million, driven by a 91% increase in packs sold compared to 2024 [3][19] - The gross profit margin is expected to rise to 70%-75% over the next couple of years, reflecting economies of scale and reduced distribution costs [20][47] - The company reported a significant reduction in selling expenses as a percentage of sales, dropping from nearly 60% in 2024 to 33% in 2025 [21][23] Business Line Data and Key Metrics Changes - The establishment of over 180 professional sales teams has enabled Hua Medicine to cover over 3,000 hospitals and reach over 150,000 patients in mainland China [4][5] - The commercialization strategy has shifted from relying on partners to an in-house team, which has significantly improved market access and sales performance [4][19] Market Data and Key Metrics Changes - The company has extended its glucokinase activator program into the glucose homeostasis technology platform, targeting the 100 million diabetes patients in Southeast Asia [3][16] - The market exclusivity for dorzagliatin has been extended to 2034, supported by government policies that maintain the same reimbursement price for 2026 and 2027 [5][39] Company Strategy and Development Direction - Hua Medicine is focusing on expanding its market access and commercialization capabilities, particularly in the Greater Bay Area, to push dorzagliatin into Southeast Asia [16][18] - The company is also exploring new indications for dorzagliatin, including obesity, NASH, and early Alzheimer's disease, leveraging its glucose homeostasis technology platform [18][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sales targets of CNY 1 billion by 2027, citing strong patent protection, stable pricing, and effective promotion strategies as key factors [31][34] - The management highlighted the importance of real-world evidence and investigator-initiated trials in demonstrating the drug's efficacy and safety, which are expected to drive future growth [22][43] Other Important Information - Hua Medicine has received IND approval for a fixed-dose combination of dorzagliatin with metformin, with an NDA filing expected in 2027 [18][27] - The company is actively seeking partnerships for its second-generation products and exploring in-licensing opportunities to enhance its pipeline [28][58] Q&A Session Summary Question: What are the sales targets for the next two years? - Management remains confident in achieving CNY 1 billion in sales by 2027, supported by patent protection and stable pricing strategies [31][34] Question: What is the progress on the pipeline for the second generation of GKA? - Management indicated that promising data from ongoing studies will guide interactions with regulatory agencies for product launch [32][37] Question: What are the expectations for operating expenses in the coming years? - Selling expenses are expected to stabilize around 30-35%, while R&D expenses will be maintained at approximately 30% to support ongoing projects [44][51]

Financial Data and Key Metrics Changes - The company's ROE for 2025 is reported at 10.58%, showing a significant increase from previous periods [1][2] - Total revenue for 2025 is projected to be 2.49 billion, reflecting a growth of 28% compared to the previous year [1] - The company achieved a net profit margin of 37.7% in 2025, indicating a strong performance [1] Business Line Data and Key Metrics Changes - The IPO segment generated 1.318 billion in revenue, with a notable increase of 90% year-over-year [1] - The ETF business line showed a growth rate of 35.73% in 2025, indicating robust demand in this area [2] - The FICC (Fixed Income, Currencies, and Commodities) segment also demonstrated strong performance, contributing significantly to overall revenue [2] Market Data and Key Metrics Changes - The company reported a 4.8% increase in market share within the ESG (Environmental, Social, and Governance) investment sector [1] - The total assets under management (AUM) reached 151.7 billion, up from 190.6 billion in the previous year [1] - The REITs (Real Estate Investment Trusts) market segment is projected to grow by 18% in 2025 [2] Company Strategy and Development Direction - The company is focusing on expanding its presence in the ESG investment space, aligning with global trends towards sustainable investing [1] - There is a strategic emphasis on enhancing the ETF offerings to capture a larger market share [2] - The management highlighted plans to leverage technology and AI to improve operational efficiency and client service [1] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the overall market conditions, citing strong demand across various segments [1] - The company anticipates continued growth in the IPO and ETF markets, driven by favorable economic conditions [2] - There is a cautious outlook regarding potential regulatory changes that could impact the investment landscape [1] Other Important Information - The company is committed to maintaining a strong focus on risk management practices to navigate market volatility [1] - There is an ongoing investment in technology to enhance trading platforms and client engagement [2] Q&A Session Summary Question: What are the expectations for the IPO market in 2025? - Management indicated that they expect a robust IPO market, driven by increased investor interest and favorable economic conditions [1] Question: How does the company plan to address potential regulatory changes? - The management stated that they are actively monitoring regulatory developments and are prepared to adapt strategies accordingly [2] Question: What initiatives are being taken to enhance ESG offerings? - The company is investing in research and development to create innovative ESG products that meet growing investor demand [1]

Financial Data and Key Metrics Changes - The company recorded core earnings of RMB 397 million for the year, but reported a loss attributable to shareholders of RMB 1.78 billion due to non-cash fair value adjustments and inventory impairment [3][4] - Total revenue was approximately RMB 4.1 billion, with property sales revenue around RMB 500 million and total rental income of RMB 3.6 billion, reflecting a 2% increase in rental income [14][16] - The net gearing ratio stood at 52%, supported by cash and bank deposits of RMB 6.5 billion, with total debt reduced by 12% year-on-year [4][20] Business Line Data and Key Metrics Changes - The retail portfolio showed strong growth, with retail sales and shopper traffic increasing by 15% and 12% respectively [5][44] - Property sales included residential sales of RMB 7.2 billion and commercial property sales of RMB 670 million, with a total contract sales of RMB 7.9 billion [28] - The office segment faced challenges, with Shanghai citywide rents down by about 11% year-on-year due to increased supply and dampened demand [12] Market Data and Key Metrics Changes - Nationwide sales volume and value declined by 8.7% and 12.6% year-on-year, respectively, indicating a challenging operating environment [9][10] - In Shanghai, the primary housing market saw a slight dip in sales volume, but average selling prices rose, driven by high-quality projects [33] - International inbound tourism in Shanghai grew by about 40%, contributing positively to retail demand [11] Company Strategy and Development Direction - The company aims to leverage its upgraded Xintiandi brand and luxury residential living brand, Lakeville, to expand its land bank through an asset-light strategy [13][34] - The focus will remain on top-tier cities, particularly Shanghai, while maintaining financial prudence in new investments [34] - The SLI strategy will be employed to introduce financial investors into mature commercial assets, broadening capital sources and managing risks [35][36] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenging operating environment due to geopolitical uncertainties and subdued consumer confidence, but noted resilient demand for high-quality assets [2][3] - There are early signs of stabilization in the market, with government policies shifting towards achieving sustained market stabilization [31][32] - The company expects rental income to continue growing and aims to maintain a healthy financial condition [27] Other Important Information - The company has reduced its Scope 1 and 2 emissions by 57% against the 2019 base year and received a GRESB 5-Star and HKQAA ESG AA Rating [7] - New projects such as Xintiandi Dongtai Li and KIC PARK have been opened, contributing positively to rental income [46][49] Q&A Session Summary Question: What are the company's expectations for the property market in 2026? - The company anticipates a shift in policy focus towards stability, indicating that the most difficult phase may be behind [31] Question: How is the company managing its debt and liquidity? - The company has pivoted its financing from offshore to onshore, reducing offshore exposure to less than 20% and lowering the average cost of debt to approximately 4.2% [25][26] Question: What strategies are in place to enhance retail performance? - The company plans to capitalize on inbound tourism and implement innovative marketing events to drive shopper traffic and tenant sales [51]

Financial Data and Key Metrics Changes - The company recorded core earnings of CNY 397 million for the year, but reported a loss attributable to shareholders of CNY 1.78 billion due to non-cash fair value adjustments and inventory impairment [3][4] - Total revenue was approximately CNY 4.1 billion, with property sales revenue around CNY 500 million and total rental income of CNY 3.6 billion, reflecting a 2% increase in rental income [14][16] - The net gearing ratio stood at 52%, supported by cash and bank deposits of CNY 6.5 billion, with total debt reduced by 12% year-on-year [4][20] Business Line Data and Key Metrics Changes - The retail portfolio showed strong growth, with retail sales increasing by 15% and shopper traffic by 12% [5][42] - Property sales included residential sales of CNY 7.2 billion and commercial property sales of CNY 670 million, with a total contract sales of CNY 7.9 billion [27][28] - The office segment faced challenges, with Shanghai citywide rents down by about 11% year-on-year due to increased supply and dampened demand [12][43] Market Data and Key Metrics Changes - Nationwide sales volume and value declined by 8.7% and 12.6% year-on-year, respectively, indicating a challenging operating environment [9][10] - In Shanghai, the primary housing market saw a slight dip in sales volume, but average selling prices rose, driven by high-quality projects [30][31] - International inbound tourism in Shanghai grew by about 40%, contributing positively to retail demand [11] Company Strategy and Development Direction - The company aims to leverage its upgraded Xintiandi brand and luxury residential living brand, Lakeville, to expand its land bank through an asset-light strategy [13][33] - The focus will remain on top-tier cities, particularly Shanghai, while maintaining financial prudence in new investments [33] - The SLI strategy will be employed to introduce financial investors into mature commercial assets, broadening capital sources and managing risks [34][35] Management's Comments on Operating Environment and Future Outlook - The management highlighted the challenging operating environment due to geopolitical uncertainties and subdued consumer confidence, but noted resilient demand for high-quality assets [2][3] - There are early signs of stabilization in the market, with government policies shifting towards supporting market recovery [30][31] - The company expects rental income to continue growing and aims to maintain a healthy financial condition [26] Other Important Information - The company has reduced its Scope 1 and 2 emissions by 57% against the 2019 base year and received a GRESB five-star rating [7] - New projects like Xintiandi Dongtai Li and K11 SEEK Park have started contributing to rental income, with positive market responses [45][46] Q&A Session Summary Question: What are the company's strategies for navigating the current market challenges? - The company will focus on maintaining financial prudence, leveraging its brand strengths, and expanding strategic partnerships to drive sustainable development [33][34] Question: How does the company plan to address the challenges in the office segment? - The company aims to maintain high occupancy rates through flexible leasing strategies and enhanced tenant engagement [49]